Announcements Trials
Browse Landscape

Phase

Phase NA 26Phase 2 25Phase 1 12Phase 1/2 11Phase 3 5Phase EARLY_PHASE1 4Phase 4 1Phase 2/3 1

Status

Recruiting 523Active not recruiting 434Completed 108Not yet recruiting 102Terminated 26Withdrawn 5Enrolling by invitation 4Suspended 3

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Lymphoid 1

Conditions

Urologic Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasms 2Urinary Bladder Neoplasms 1Thymoma 1Recurrence 1Lymphoma, Follicular 1

Interventions

fludarabine 1Vincristine 1Rituximab 1Radiotherapy 1Prednisone 1Lenalidomide 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × 90 days × Clear all
NCT07551544 2026-05-19

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

ImmunityBio, Inc.

Phase 3 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT02633514 2026-04-27

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Fudan University

Phase 3 Withdrawn
Thoracic

Thymoma

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

NCT07313891 2026-03-17

BOOST

Relmada Therapeutics, Inc.

Phase 3 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT07342517 2026-03-17

RESCUE

Relmada Therapeutics, Inc.

Phase 3 Withdrawn
Genitourinary

Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡